8 results on '"Sager, Hendrik B."'
Search Results
2. Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes.
- Author
-
Lahu, Shqipdona, Behnes, Michael, Ndrepepa, Gjin, Neumann, Franz-Josef, Sibbing, Dirk, Bernlochner, Isabell, Menichelli, Maurizio, Mayer, Katharina, Richardt, Gert, Gewalt, Senta, Angiolillo, Dominick J., Coughlan, John Joseph, Aytekin, Alp, Witzenbichler, Bernhard, Hochholzer, Willibald, Cassese, Salvatore, Kufner, Sebastian, Xhepa, Erion, Sager, Hendrik B., and Joner, Michael
- Abstract
Copyright of Revista Española de Cardiología (18855857) is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
3. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate.
- Author
-
Wöhrle, Jochen, Seeger, Julia, Lahu, Shqipdona, Mayer, Katharina, Bernlochner, Isabell, Gewalt, Senta, Menichelli, Maurizio, Witzenbichler, Bernhard, Hochholzer, Willibald, Sibbing, Dirk, Cassese, Salvatore, Angiolillo, Dominick J., Hemetsberger, Rayyan, Valina, Christian, Kufner, Sebastian, Xhepa, Erion, Hapfelmeier, Alexander, Sager, Hendrik B., Joner, Michael, and Richardt, Gert
- Abstract
The aim of this study was to assess the safety and efficacy of ticagrelor versus prasugrel for patients with acute coronary syndrome (ACS) according to their estimated glomerular filtration rates (eGFRs). The outcomes of ticagrelor versus prasugrel in patients with ACS according to eGFR have not been defined. Patients (n = 4,012) were categorized into 3 groups: low eGFR (<60 mL/min/1.73 m
2 ), intermediate eGFR (≥60 and <90 mL/min/1.73 m2 ), and high eGFR (≥90 mL/min/1.73 m2 ). The primary endpoint was a composite of all-cause death, myocardial infarction, and stroke; the secondary safety endpoint was Bleeding Academic Research Consortium types 3 to 5 bleeding, both at 1 year. Patients with low eGFRs had a higher risk for the primary endpoint compared with patients with intermediate eGFRs (adjusted HR: 1.89; 95% CI: 1.46-2.46]) and those with high eGFRs (adjusted HR: 2.33; 95% CI: 1.57-3.46). A risk excess for low eGFR was also observed for bleeding (adjusted HR: 1.55 [95% CI: 1.12-2.13] vs intermediate eGFR; adjusted HR: 1.59 [95% CI: 1.01-2.50] vs high eGFR). However, eGFR did not affect the relative efficacy and safety of ticagrelor versus prasugrel. In patients with low eGFR, the primary endpoint occurred in 20.5% with ticagrelor and in 14.7% with prasugrel (HR: 1.47; 95% CI: 1.04-2.08; P = 0.029); there was no significant difference in bleeding. These results show that among patients with ACS, reduction of eGFR is associated with increased risk for ischemic and bleeding events but has no significant impact on the relative efficacy and safety of ticagrelor versus prasugrel. (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome [ISAR-REACT 5]; NCT01944800) [Display omitted] [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
4. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome and High Bleeding Risk.
- Author
-
Lahu, Shqipdona, Presch, Antonia, Ndrepepa, Gjin, Menichelli, Maurizio, Valina, Christian, Hemetsberger, Rayyan, Witzenbichler, Bernhard, Bernlochner, Isabell, Joner, Michael, Xhepa, Erion, Hapfelmeier, Alexander, Kufner, Sebastian, Rifatov, Nonglag, Sager, Hendrik B., Mayer, Katharina, Kessler, Thorsten, Laugwitz, Karl-Ludwig, Richardt, Gert, Schunkert, Heribert, and Neumann, Franz-Josef
- Abstract
Background: The relative efficacy and safety of more potent P2Y
12 inhibitors in patients with acute coronary syndrome and high bleeding risk (HBR) undergoing percutaneous coronary intervention remains unclear. We aimed to study the treatment effect of ticagrelor and prasugrel in percutaneous coronary intervention patients presenting with acute coronary syndrome and HBR. Methods: This post hoc analysis of the ISAR-REACT 5 trial (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5) included patients with acute coronary syndrome undergoing percutaneous coronary intervention, randomized to ticagrelor or prasugrel, in whom HBR was defined as per Academic Research Consortium criteria. The primary (efficacy) end point was the composite of all-cause death, myocardial infarction, or stroke. The secondary (safety) end point was Bleeding Academic Research Consortium type 3 to 5 bleeding. Outcomes were assessed 12 months after randomization. Results: Out of the 3239 patients included in this analysis, 486 fulfilled the criteria for Academic Research Consortium-HBR definition (HBR group; ticagrelor, n=230 and prasugrel, n=256), while 2753 did not (non-HBR group; ticagrelor, n=1375 and prasugrel, n=1378). Compared with the non-HBR group, the HBR group had a higher risk for the primary (hazard ratio [HR]=3.57 [95% CI, 2.79–4.57]; P <0.001) and secondary end point (HR=2.94 [2.17–3.99]; P <0.001). In the HBR group, the primary (HR=1.09 [0.73–1.62]) and secondary (HR=1.18 [0.67–2.08]) end points were not significantly different between patients assigned to ticagrelor and prasugrel. In the non-HBR group, the primary end point (HR=1.62 [1.19–2.20]) occurred more frequently in patients assigned to ticagrelor as compared to patients assigned to prasugrel, without difference in safety (HR=1.08 [0.74–1.58]). There was no significant treatment allocation-by-HBR status interaction with respect to the primary (P for interaction=0.12) or secondary (P for interaction=0.80) end points. Conclusions: In patients with acute coronary syndrome undergoing percutaneous coronary intervention, HBR status increased both ischemic and bleeding risk without significant impact on the relative efficacy and safety of either ticagrelor or prasugrel. These results warrant confirmation in larger cohorts. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01944800. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
5. Access Route and Clinical Outcomes After Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Undergoing Invasive Treatment Strategy.
- Author
-
Hemetsberger, Rayyan, Richardt, Gert, Lahu, Shqipdona, Valina, Christian, Menichelli, Maurizio, Abdelghani, Mohammad, Wöhrle, Jochen, Toelg, Ralph, Witzenbichler, Bernhard, Mankerious, Nader, Liebetrau, Christoph, Bernlochner, Isabell, Hamm, Christian W., Allali, Abdelhakim, Joner, Michael, Fusaro, Massimiliano, Xhepa, Erion, Hapfelmeier, Alexander, Kufner, Sebastian, and Sager, Hendrik B.
- Subjects
- *
ACUTE coronary syndrome , *PRASUGREL , *TICAGRELOR , *TREATMENT effectiveness , *CORONARY angiography , *RESEARCH , *MEDICAL care , *MYOCARDIAL infarction , *EVALUATION research , *CARDIOVASCULAR system , *COMPARATIVE studies , *PLATELET aggregation inhibitors - Abstract
Background: Whether the access site influences the comparative efficacy and safety of ticagrelor and prasugrel in patients with acute coronary syndrome (ACS) undergoing invasive treatment strategy remains unstudied.Methods: This post-hoc analysis included ACS patients undergoing invasive treatment via radial or femoral access and randomized to either ticagrelor or prasugrel in the ISAR-REACT 5 trial. The primary efficacy endpoint was the composite of death, myocardial infarction (MI) or stroke, safety endpoint was BARC 3 to 5 bleeding. Outcomes were assessed out to 12 months after randomization.Results: Out of 4018 patients, 3984 underwent invasive treatment via radial or femoral access. 1479 had coronary angiography via radial access (ticagrelor, N = 748; prasugrel, N = 731) and 2505 via femoral access (ticagrelor, N = 1245; prasugrel, N = 1260). There was no interaction between access route and assignment to either ticagrelor or prasugrel regarding the primary efficacy or safety endpoints (P for interaction≥0.616). In the radial group, the primary efficacy endpoint (7.6% versus 5.8%, HR: 1.32 [0.88-1.97], P = 0.151) and the safety endpoint (4.3% versus 3.0%, HR: 1.36, [0.73-1.31], P = 0.300) were not statistically different in patients receiving either ticagrelor or prasugrel. In the femoral group, the primary efficacy endpoint occurred more frequently in patients assigned to ticagrelor as compared to prasugrel (10.3% versus 7.3%, HR: 1.44 [1.10-1.88], P = 0.006) without significant difference in terms of safety endpoint (6.4% versus 5.8%, HR: 1.14, [0.81-1.60], P = 0.470).Conclusions: In patients with ACS undergoing an invasive treatment strategy, the access route does not influence the comparative efficacy and safety of ticagrelor and prasugrel.Clinical Trial Registration: NCT01944800. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
6. Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes.
- Author
-
Lahu, Shqipdona, Ndrepepa, Gjin, Gewalt, Senta, Schüpke, Stefanie, Pellegrini, Costanza, Bernlochner, Isabell, Aytekin, Alp, Neumann, Franz-Josef, Menichelli, Maurizio, Richardt, Gert, Cassese, Salvatore, Xhepa, Erion, Kufner, Sebastian, Sager, Hendrik B., Joner, Michael, Ibrahim, Tareq, Fusaro, Massimiliano, Laugwitz, Karl-Ludwig, Schunkert, Heribert, and Kastrati, Adnan
- Subjects
- *
ACUTE coronary syndrome , *TICAGRELOR , *INTRA-abdominal hypertension , *PRASUGREL , *STROKE , *TREATMENT effectiveness , *MYOCARDIAL infarction , *CIGARETTE smokers , *NON-smokers - Abstract
The efficacy and safety of ticagrelor versus prasugrel according to smoking status in patients with acute coronary syndromes (ACS) are not known. We assessed the efficacy and safety of ticagrelor versus prasugrel according to smoking status in patients with ACS undergoing invasive management. This pre-specified analysis of the ISAR-REACT 5 trial included 1349 smokers and 2652 nonsmokers randomized to receive ticagrelor or prasugrel. The primary endpoint was the incidence of death, myocardial infarction, or stroke; the secondary endpoint was the incidence of Bleeding Academic Research Consortium (BARC) type 3 to 5 bleeding (both endpoints assessed at 12 months). There was no significant treatment arm-by-smoking status interaction regarding the efficacy outcome. The primary endpoint occurred in 47 patients (7.0%) in the ticagrelor group and 41 patients (6.2%) in the prasugrel group in smokers (hazard ratio [HR] = 1.15; 95% confidence interval [CI] 0.76–1.75; P = 0.510) and in 133 patients (10.2%) in the ticagrelor group and 94 patients (7.2%) in the prasugrel group in nonsmokers (HR = 1.44 [1.10–1.87]; P = 0.007; P for interaction = 0.378). The secondary endpoint occurred in 27 patients (4.6%) in the ticagrelor group and 33 patients (5.6%) in the prasugrel group in smokers (HR = 0.81 [0.49–1.35]; P = 0.412) and in 66 patients (6.0%) in the ticagrelor group and 46 patients (4.4%) in the prasugrel group in nonsmokers (HR = 1.38 [0.94–2.01]; P = 0.097). In patients with ACS undergoing an invasive management strategy, the smoking status did not significantly interact with the relative treatment effect of ticagrelor vs. prasugrel. NCT01944800 • In ACS patients, ticagrelor and prasugrel showed similar efficacy regardless of smoking status. • Bleeding risk was comparable between ticagrelor and prasugrel in smokers and nonsmokers. • Smoking status does not interfere with the relative treatment effect of ticagrelor vs. prasugrel. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
- Author
-
Aytekin, Alp, Ndrepepa, Gjin, Neumann, Franz-Josef, Menichelli, Maurizio, Mayer, Katharina, Wöhrle, Jochen, Bernlochner, Isabell, Lahu, Shqipdona, Richardt, Gert, Witzenbichler, Bernhard, Sibbing, Dirk, Cassese, Salvatore, Angiolillo, Dominick J., Valina, Christian, Kufner, Sebastian, Liebetrau, Christoph, Hamm, Christian W., Xhepa, Erion, Hapfelmeier, Alexander, and Sager, Hendrik B.
- Subjects
- *
PERCUTANEOUS coronary intervention , *MYOCARDIAL infarction , *TICAGRELOR , *PRASUGREL , *MEDICAL equipment , *RESEARCH , *STROKE , *TIME , *RESEARCH methodology , *MEDICAL care , *NEUROTRANSMITTERS , *SURGICAL stents , *MEDICAL cooperation , *EVALUATION research , *CARDIOVASCULAR system , *MEDICAL care research , *DISEASE relapse , *TREATMENT effectiveness , *RISK assessment , *COMPARATIVE studies , *RANDOMIZED controlled trials , *DRUGS , *PLATELET aggregation inhibitors , *HEMORRHAGE - Abstract
Background: Data on the comparative efficacy and safety of ticagrelor versus prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention are limited. We assessed the efficacy and safety of ticagrelor versus prasugrel in a head-to-head comparison in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention.Methods: In this prespecified subgroup analysis, we included 1653 patients with ST-segment-elevation myocardial infarction randomized to receive ticagrelor or prasugrel in the setting of the ISAR REACT-5 trial (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5). The primary end point was the incidence of death, myocardial infarction, or stroke at 1 year after randomization. The secondary end point was the incidence of bleeding defined as BARC (Bleeding Academic Research Consortium) type 3 to 5 bleeding at 1 year after randomization.Results: The primary end point occurred in 83 patients (10.1%) in the ticagrelor group and in 64 patients (7.9%) in the prasugrel group (hazard ratio, 1.31 [95% CI, 0.95-1.82]; P=0.10). One-year incidence of all-cause death (4.9% versus 4.7%; P=0.83), stroke (1.3% versus 1.0%; P=0.46), and definite stent thrombosis (1.8% versus 1.0%; P=0.15) did not differ significantly in patients assigned to ticagrelor or prasugrel. One-year incidence of myocardial infarction (5.3% versus 2.8%; hazard ratio, 1.95 [95% CI, 1.18-3.23]; P=0.010) was higher with ticagrelor than with prasugrel. BARC type 3 to 5 bleeding occurred in 46 patients (6.1%) in the ticagrelor group and in 39 patients (5.1%) in the prasugrel group (hazard ratio, 1.22 [95% CI, 0.80-1.87]; P=0.36).Conclusions: In patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention, there was no significant difference in the primary end point between prasugrel and ticagrelor. Ticagrelor was associated with a significant increase in the risk for recurrent myocardial infarction. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01944800. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
8. Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
- Author
-
Valina, Christian, Neumann, Franz-Josef, Menichelli, Maurizio, Mayer, Katharina, Wöhrle, Jochen, Bernlochner, Isabell, Aytekin, Alp, Richardt, Gert, Witzenbichler, Bernhard, Sibbing, Dirk, Cassese, Salvatore, Angiolillo, Dominick J, Kufner, Sebastian, Liebetrau, Christoph, Hamm, Christian W, Xhepa, Erion, Hapfelmeier, Alexander, Sager, Hendrik B, Wustrow, Isabel, and Joner, Michael
- Subjects
- *
TREATMENT of acute coronary syndrome , *RESEARCH , *RESEARCH methodology , *NEUROTRANSMITTERS , *ACUTE coronary syndrome , *EVALUATION research , *MEDICAL cooperation , *CORONARY angiography , *COMPARATIVE studies , *RANDOMIZED controlled trials , *PLATELET aggregation inhibitors , *DRUGS , *DISEASE complications - Abstract
Background: Current guidelines recommend intensified platelet inhibition by prasugrel or ticagrelor in patients with unstable angina (UA) or non-ST-segment elevation (NSTE) myocardial infarction (MI).Objectives: This study sought to investigate the benefits and risks of ticagrelor as compared with prasugrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) and planned invasive management.Methods: This post hoc analysis combines the pre-specified subgroups of UA and NSTEMI of the randomized ISAR-REACT 5 trial. It included 1,179 patients assigned to ticagrelor and 1,186 assigned to prasugrel. Ticagrelor was started immediately after randomization and prasugrel after coronary angiography. The primary endpoint was a composite of death, MI, or stroke during 1-year follow-up, and the safety endpoint was Bleeding Academic Research Consortium class 3-5.Results: The primary endpoint was reached in 101 (8.7%) patients in the ticagrelor and in 73 (6.3%) patients in the prasugrel group (hazard ratio [HR]: 1.41; 95% confidence interval [CI]: 1.04 to 1.90). The HR for all-cause death was 1.43 (95% CI: 0.93 to 2.21) and that for MI 1.43 (95% CI: 0.94 to 2.19). The safety endpoint occurred in 49 (5.2%) patients in the ticagrelor and in 41 (4.7%) patients in the prasugrel group (HR: 1.09; 95% CI: 0.72 to 1.65). Landmark analysis revealed persistence of the efficacy advantage with prasugrel after the first month.Conclusions: In patients with NSTE-ACS, we found that prasugrel was superior to ticagrelor in reducing the combined 1-year risk of death, MI, and stroke without increasing the risk of bleeding. Due to the post hoc nature of the analysis, these findings need confirmation by further studies. (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome; NCT01944800). [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.